Vertex Pharmaceutic (VRTX) Stock Price, Quote & News

Company Profile

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for peo...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 341 6100

Website: www.vrtx.com

Address:

50 Northern Avenue, Boston, United States

svertical1 Jun. 4 at 2:31 PM

$VRTX This board needs some action. If you read this without ‘loving’ it. You’re a Fool!

0 · Reply

svertical1 Jun. 4 at 2:26 PM

$VRTX M&A! A 5% position in ImmunityBio and Vertex will have coverage of All Cancer and All disease.

0 · Reply

svertical1 Jun. 4 at 2:23 PM

$VRTX Big question- has Vertex learned their lesson on pricing. They don’t need another Jouravx Dud. Price as category killer… not as incremental saver of overall society healthcare ills… Anyone involved in Journavx pricing should be long gone from Vertex. Clear communication with FDA regarding de-graduated pricing schedule based on additional approvals.

0 · Reply

svertical1 Jun. 4 at 2:15 PM

$VRTX Stock should be at a $1000+. Per Grok: Yes, if the trial data and expectations continue to hold, povetacicept (pove) is positioned as a strong best-in-class or highly competitive candidate in several of these indications: •IgA Nephropathy (IgAN) •Lupus Nephritis (LN) and ANCA-Associated Vasculitis (AAV) •Generalized Myasthenia Gravis

0 · Reply

svertical1 Jun. 4 at 2:04 PM

$VRTX Way underestimated! Bigger than CF! Will grow faster than CF! Additional conditions will be added faster than CF expansion! https://grok.com/share/c2hhcmQtMw_e25de83d-3e78-4bc6-a8b4-fcc2082a1df7

0 · Reply

svertical1 Jun. 4 at 1:53 PM

$VRTX Dr. Reshma Kewalramani, President and Chief Executive Officer will participate in a fireside chat on Wednesday, June 10, 2026, at 11:20 a.m. ET. •Povi-Approval anytime, Manufacturing/Distribution Plan- did they learn from Journavx… •Pipeline- Robust - What’s next •M&A— Near Rev acquisitions and deals? •Pain update- DNP, Chronic

0 · Reply

DinoMcnuggets Jun. 2 at 5:07 PM

$VRTX Keeping an eye on this. Bought a position today at 427 for a sympathy bounce play on the immense biotech weakness. But if this hits 404$ I think this is a very strong buy.

0 · Reply

Scarlasfly Jun. 2 at 1:53 PM

$VRTX Day after day...🤬

0 · Reply

pnvoss Jun. 2 at 10:42 AM

$SPY $ABNB and $VRTX are good companies and cash rich

1 · Reply

FireLife45 Jun. 1 at 9:23 PM

$VRTX The renal regime will surpass the CF franchise in terms of size, encompassing other approved drugs and a robust pipeline, as demonstrated by its diversified business model. While CF will continue to generate cash, the renal regime will emerge as the primary revenue source. The approval of POVI marks the dawn of a new era for $VRTX

0 · Reply

Vertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10

2026-06-01T12:42:04.000Z - 3 days ago

Vertex announces U.S. FDA accepted BLA submission for povetacicept

Jun 1, 2026, 8:00 AM EDT - 3 days ago

Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy

May 29, 2026, 9:00 AM EDT - 6 days ago

Vertex Pharmaceuticals Transcript: Bernstein 42nd Annual Strategic Decisions Conference

2026-05-27T09:22:01.000Z - 8 days ago

Vertex Pharmaceuticals assumed with a Buy at Truist

2026-05-21T17:00:12.000Z - 14 days ago

Vertex announces Health Canada acceptance of NDS for suzetrigine

May 19, 2026, 2:35 PM EDT - 16 days ago

Vertex Pharmaceuticals Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 11, 2026, 4:00 PM EDT - 23 days ago

Vertex to Participate in Upcoming May Investor Conferences

2026-05-07T10:11:22.000Z - 4 weeks ago

Vertex Pharmaceuticals price target raised to $615 from $607 at Barclays

2026-05-07T07:48:12.000Z - 4 weeks ago

Vertex Pharmaceuticals announces Casgevy reimbursement agreement

May 6, 2026, 7:01 AM EDT - 4 weeks ago

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany

2026-05-05T12:54:50.000Z - 4 weeks ago

Vertex Pharmaceuticals price target raised to $616 from $612 at Morgan Stanley

2026-05-05T11:48:44.000Z - 4 weeks ago

Vertex Pharmaceuticals price target raised to $543 from $541 at RBC Capital

2026-05-05T10:49:13.000Z - 4 weeks ago

Vertex Pharmaceuticals price target lowered to $436 from $437 at Canaccord

2026-05-05T10:47:35.000Z - 4 weeks ago

Vertex Pharmaceuticals price target lowered to $572 from $577 at Bernstein

SION

2026-05-04T22:25:16.000Z - 4 weeks ago

Moderna updates on Cystic Fibrosis collaboration with Vertex Pharmaceuticals

MRNA

May 4, 2026, 4:30 PM EDT - 4 weeks ago

Vertex Pharmaceuticals Earnings Call Transcript: Q1 2026

May 4, 2026, 4:30 PM EDT - 4 weeks ago

Vertex Pharmaceuticals Earnings release: Q1 2026

May 4, 2026, 4:30 PM EDT - 4 weeks ago

Vertex Pharmaceuticals Slides: Q1 2026

May 4, 2026, 4:30 PM EDT - 4 weeks ago

Vertex Pharmaceuticals Quarterly report: Q1 2026

2026-05-04T20:08:07.000Z - 4 weeks ago

Vertex Pharmaceuticals reports Q1 EPS $4.02, consensus $4.31

2026-05-04T20:07:54.000Z - 4 weeks ago

Vertex Pharmaceuticals affirms FY26 revenue $12.95B-$13.1B, consensus $13.05B

May 4, 2026, 4:04 PM EDT - 4 weeks ago

Vertex tops profit estimates as sales of new cystic fibrosis drug surge

May 4, 2026, 4:01 PM EDT - 4 weeks ago

Vertex Reports First Quarter 2026 Financial Results

2026-05-04T18:46:06.000Z - 4 weeks ago

Notable companies reporting after market close

DUOL GRAB ON PGR PINS PLTR PSKY

Apr 29, 2026, 8:00 AM EDT - 5 weeks ago

Vertex Pharmaceuticals Proxy statement: Proxy filing

Apr 6, 2026, 4:00 PM EDT - 2 months ago

Vertex to Announce First Quarter 2026 Financial Results on May 4th

Apr 2, 2026, 8:00 AM EDT - 2 months ago

Vertex Pharmaceuticals Proxy statement: Proxy filing

Apr 2, 2026, 8:00 AM EDT - 2 months ago

Vertex Pharmaceuticals Proxy statement: Proxy filing

Apr 1, 2026, 7:30 AM EDT - 2 months ago

Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States

Mar 18, 2026, 2:23 PM EDT - 2 months ago

TrumpRx lists many medicines at prices higher than paid in UK

ABBV AMGN AZN BMY GILD GSK JNJ

Mar 11, 2026, 11:30 AM EDT - 3 months ago

Vertex Pharmaceuticals Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 10, 2026, 1:22 PM EDT - 3 months ago

This Pharmaceutical Stock Is Leading the S&P 500 Higher Tuesday, After 'Remarkable' Trial Results

Mar 10, 2026, 10:54 AM EDT - 3 months ago

Vertex passes key test In quest to treat kidney diseases

Mar 10, 2026, 10:00 AM EDT - 3 months ago

Vertex Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 4:13 PM EDT - 3 months ago

Vertex's kidney disease drug meets main goal in late-stage trial

Mar 9, 2026, 4:02 PM EDT - 3 months ago

Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy

Mar 5, 2026, 4:00 PM EST - 3 months ago

Vertex to Participate in Upcoming March Investor Conferences

Mar 5, 2026, 10:00 AM EST - 3 months ago

Vertex to Present New Data on JOURNAVX® That Demonstrates Effective Pain Management Following Aesthetic and Reconstructive Procedures

Mar 3, 2026, 9:10 AM EST - 3 months ago

Vertex Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Feb 17, 2026, 4:00 PM EST - 3 months ago

Vertex to Participate in TD Cowen 46th Annual Health Care Conference on March 3

Feb 12, 2026, 4:30 PM EST - 3 months ago

Vertex Pharmaceuticals Earnings Call Transcript: Q4 2025

Feb 12, 2026, 4:30 PM EST - 3 months ago

Vertex Pharmaceuticals Annual report: Q4 2025

Feb 12, 2026, 4:30 PM EST - 3 months ago

Vertex Pharmaceuticals Earnings release: Q4 2025

Feb 12, 2026, 4:30 PM EST - 3 months ago

Vertex Pharmaceuticals Slides: Q4 2025

Feb 12, 2026, 4:06 PM EST - 3 months ago

Vertex Pharma forecasts 2026 revenue in-line, expects growth in cystic fibrosis treatments

Feb 12, 2026, 4:01 PM EST - 3 months ago

Vertex Reports Fourth Quarter and Full Year 2025 Financial Results

Feb 2, 2026, 10:08 PM EST - 4 months ago

WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager

Jan 22, 2026, 1:19 PM EST - 4 months ago

Final Trades: Vertex Pharma, Kimberly-Clark, S&P Global and Exxon Mobil

KMB XOM SPGI

Jan 20, 2026, 4:00 PM EST - 4 months ago

Vertex to Announce Fourth Quarter and Full Year 2025 Financial Results on February 12th

Jan 12, 2026, 5:15 PM EST - 5 months ago

Vertex Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 5:15 PM EST - 5 months ago

Vertex Pharmaceuticals Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 11, 2026, 5:00 PM EST - 5 months ago

Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings

Dec 22, 2025, 4:00 PM EST - 5 months ago

Vertex to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12

Dec 6, 2025, 7:04 AM EST - 6 months ago

Vertex's gene therapy shows promise in younger children with blood disorders

Dec 6, 2025, 7:01 AM EST - 6 months ago

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions

Dec 3, 2025, 9:00 AM EST - 6 months ago

Vertex Pharmaceuticals Transcript: Citi Annual Global Healthcare Conference 2025

Nov 19, 2025, 4:00 PM EST - 7 months ago

Vertex to Participate in the Citi's 2025 Global Healthcare Conference on December 3

Nov 11, 2025, 10:15 AM EST - 7 months ago

Vertex Pharmaceuticals Transcript: UBS Global Healthcare Conference 2025

Nov 8, 2025, 8:00 PM EST - 7 months ago

Vertex Pharmaceuticals Transcript: Study Update

Nov 8, 2025, 8:00 PM EST - 7 months ago

Vertex Pharmaceuticals Slides: Study Update

Nov 8, 2025, 5:15 PM EST - 7 months ago

Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week

Nov 4, 2025, 1:22 PM EST - 7 months ago

Committee stocks on the move: Uber and Vertex Pharma

UBER

Nov 3, 2025, 4:30 PM EST - 7 months ago

Vertex Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 3, 2025, 4:30 PM EST - 7 months ago

Vertex Pharmaceuticals Quarterly report: Q3 2025

Nov 3, 2025, 4:30 PM EST - 7 months ago

Vertex Pharmaceuticals Earnings release: Q3 2025

Nov 3, 2025, 4:30 PM EST - 7 months ago

Vertex Pharmaceuticals Slides: Q3 2025

Nov 3, 2025, 4:20 PM EST - 7 months ago

Vertex beats quarterly estimates on cystic fibrosis demand, new drugs

Nov 3, 2025, 4:02 PM EST - 7 months ago

Vertex Reports Third Quarter 2025 Financial Results

Oct 27, 2025, 4:00 PM EDT - 7 months ago

Vertex to Participate in the UBS Global Healthcare Conference on November 11

Oct 23, 2025, 9:00 AM EDT - 8 months ago

Vertex Presents New Data Across Portfolio of Cystic Fibrosis Medicines Including ALYFTREK® at the North American Cystic Fibrosis Conference

Oct 17, 2025, 9:04 AM EDT - 8 months ago

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week

Oct 6, 2025, 4:00 PM EDT - 8 months ago

Vertex to Announce Third Quarter 2025 Financial Results on November 3rd

Oct 2, 2025, 1:31 PM EDT - 8 months ago

Final Trades: ServiceNow, Vertex Pharmaceuticals and the IJR

IJR NOW

Sep 25, 2025, 7:45 AM EDT - 9 months ago

Vertex Announces Key Advancements Across Kidney Portfolio

Sep 23, 2025, 9:00 AM EDT - 9 months ago

Vertex Partners with Basketball World Champion Jayson Tatum to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe-Acute Pain

Sep 23, 2025, 3:10 AM EDT - 9 months ago

Vertex Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2025

Sep 18, 2025, 8:30 AM EDT - 9 months ago

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia and Sickle Cell Disease in Italy

Sep 11, 2025, 9:05 AM EDT - 9 months ago

Vertex Scientists Awarded the 2025 Lasker~DeBakey Clinical Medical Research Award for Pioneering Discoveries in Cystic Fibrosis

Sep 9, 2025, 11:30 AM EDT - 9 months ago

Vertex Pharmaceuticals Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 8, 2025, 1:47 PM EDT - 9 months ago

Calls of the Day: Abbvie, Vertex, Veeva and Vistra

ABBV VEEV VST

Sep 3, 2025, 11:00 AM EDT - 9 months ago

Vertex Pharmaceuticals Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 2, 2025, 9:00 AM EDT - 9 months ago

Enlaza Therapeutics Announces Strategic Collaboration with Vertex Pharmaceuticals to Develop War-Lock Drug Conjugates and T-Cell Engagers for Improved Conditioning and Certain Autoimmune Diseases

Aug 20, 2025, 4:00 PM EDT - 10 months ago

Vertex to Participate in Upcoming September Investor Conferences

Aug 5, 2025, 10:25 AM EDT - 10 months ago

Vertex Pharmaceutical Stock Dives as Firm to Stop Developing Acute Pain Drug

Aug 4, 2025, 5:40 PM EDT - 10 months ago

Vertex tops estimates on cystic fibrosis treatment strength, new products

Aug 4, 2025, 5:13 PM EDT - 10 months ago

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger Earnings

Aug 4, 2025, 4:59 PM EDT - 10 months ago

Vertex Pharmaceuticals reports earnings, beating EPS, revenue estimates

Aug 4, 2025, 4:24 PM EDT - 10 months ago

Vertex to stop developing new painkiller as solo treatment after mid-stage study setback

Aug 4, 2025, 4:01 PM EDT - 10 months ago

Vertex Announces Results from Phase 2 Study of VX-993 for the Treatment of Acute Pain

Aug 4, 2025, 4:01 PM EDT - 10 months ago

Vertex Reports Second Quarter 2025 Financial Results

Aug 4, 2025, 5:30 AM EDT - 10 months ago

Vertex Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 4, 2025, 5:30 AM EDT - 10 months ago

Vertex Pharmaceuticals Quarterly report: Q2 2025

Aug 4, 2025, 5:30 AM EDT - 10 months ago

Vertex Pharmaceuticals Earnings release: Q2 2025

Aug 4, 2025, 5:30 AM EDT - 10 months ago

Vertex Pharmaceuticals Slides: Q2 2025

Aug 2, 2025, 12:20 AM EDT - 10 months ago

How Will VRTX Stock React To Its Upcoming Earnings?

svertical1 Jun. 4 at 2:31 PM

$VRTX This board needs some action. If you read this without ‘loving’ it. You’re a Fool!

0 · Reply

svertical1 Jun. 4 at 2:26 PM

$VRTX M&A! A 5% position in ImmunityBio and Vertex will have coverage of All Cancer and All disease.

0 · Reply

svertical1 Jun. 4 at 2:23 PM

0 · Reply

svertical1 Jun. 4 at 2:15 PM

0 · Reply

svertical1 Jun. 4 at 2:04 PM

0 · Reply

svertical1 Jun. 4 at 1:53 PM

0 · Reply

DinoMcnuggets Jun. 2 at 5:07 PM

$VRTX Keeping an eye on this. Bought a position today at 427 for a sympathy bounce play on the immense biotech weakness. But if this hits 404$ I think this is a very strong buy.

0 · Reply

Scarlasfly Jun. 2 at 1:53 PM

$VRTX Day after day...🤬

0 · Reply

pnvoss Jun. 2 at 10:42 AM

$SPY $ABNB and $VRTX are good companies and cash rich

1 · Reply

FireLife45 Jun. 1 at 9:23 PM

0 · Reply

svertical1 Jun. 1 at 3:56 PM

$VRTX The day AI takes over the final review from conflicted FDA Bureaucrats can’t come soon enough!

0 · Reply

svertical1 Jun. 1 at 3:49 PM

$VRTX I don’t think the Target PDUFA Date is meaningful. Nov gives current FDA cushion, but I’d expect much quicker approval. Trial Data is clear.

0 · Reply

FireLife45 Jun. 1 at 12:53 PM

$VRTX

0 · Reply

aachen Jun. 1 at 12:44 PM

$VRTX https://news.vrtx.com/news-releases/news-release-details/vertex-announces-us-fda-acceptance-biologics-license-application

0 · Reply

BGESGroup Jun. 1 at 11:13 AM

$ADVB $AMGN $REGN $VRTX Advanced Biomed (NASDAQ: ADVB): A Small-Cap Innovator Positioning Itself for Potential Breakthrough Growth https://open.substack.com/pub/garywallach/p/advanced-biomed-nasdaq-advb-a-small?r=3iu9hl&utm_campaign=post&utm_medium=web&showWelcomeOnShare=true

0 · Reply

DogePeoplesCoin May. 29 at 6:25 PM

$VRTX Gap fill $500 is inevitable! Release the FDA acceptance response for POVi (IgAN) now!

0 · Reply

cheechnyy May. 29 at 5:33 PM

$VRTX Where is the Journavx pain pill? No one has it.

1 · Reply

topstockalerts May. 28 at 8:45 PM

J.P. Morgan reinstated coverage on 14 large-cap biotech companies, saying the sector is nearing a major inflection point as strong drug pipelines increasingly translate into profitable and diversified businesses. The bank noted many biotech firms are approaching sustained profitability, supported by expanding product portfolios, improving margins, and upcoming clinical catalysts. The firm assigned Overweight ratings to Vertex Pharmaceuticals, Alnylam Pharmaceuticals, BeOne Medicines, United Therapeutics, Insmed, Ascendis Pharma, Jazz Pharmaceuticals, Ionis Pharmaceuticals, BioMarin Pharmaceutical, and Mirum Pharmaceuticals. Neutral ratings were maintained on BioNTech, Incyte, and Halozyme Therapeutics, while Moderna received an Underweight rating. J.P. Morgan highlighted Vertex’s expansion beyond cystic fibrosis, Alnylam’s strong Amvuttra growth, and continued momentum for BeOne Medicines and United Therapeutics. $VRTX $ALNY $ONC $UTHR $INSM

0 · Reply

Arsenal1886 May. 28 at 8:24 PM

$VRTX HOLD!

0 · Reply

kagrawala May. 28 at 6:25 PM

$VRTX i wish vrtx had a progressive dividend policy - when there is not much price action going on it is nice to get income. Hopefully they one day follow abbvs foot steps!

1 · Reply

macrossluvsrobotech May. 27 at 1:58 PM

$LXRX LOL... Go see $VRTX

0 · Reply

FireLife45 May. 26 at 10:42 AM

$VRTX

0 · Reply

Market Cap	107.89B
Revenue (ttm)	12.00B
Net Income (ttm)	3.95B
EPS (ttm)	N/A
PE Ratio	26.06
Forward PE	25.81
Profit Margin	32.94%
Debt to Equity Ratio	0.00

Volume	643,005
Avg Vol	1,252,570
Day's Range	N/A - N/A
Shares Out	253.81M
Stochastic %K	90%
Beta	0.30
Analysts	Strong Sell
Price Target	$549.76